Omega 3 Prescription Drugs Market to witness significant growth due to Rising prevalence of cardiovascular ailments as a result of the aging of the world's population

Market Highlights

The global omega 3 prescription drugs market is accounted to register a CAGR of 9.20% during the forecast period and is estimated to reach USD 2.8 Billion by 2032.

The market for omega 3 prescription drugs is experiencing steady growth due to increasing awareness of their cardiovascular benefits. These drugs, rich in essential fatty acids, cater to individuals seeking preventative and therapeutic measures for heart-related issues.

Key Players

MRFR recognizes the following companies as the key players in the global omega 3 prescription drugs market— "Abbott; Amarin Pharmaceuticals Ireland Ltd.; GSK plc; Natrapharm, Inc. (Patriot Pharmaceutical Corp.); Viatris Inc.; Grupo Ferrer Internacional, S.A.; Camber Pharmaceuticals, Inc.; Dr. Reddy’s Laboratories Ltd.; Zydus Group; Hikma Pharmaceuticals PLC"

Segment Analysis

The global omega 3 prescription drugs market has been segmented based drug, application and distribution channel.

On the basis of drug, the market is segmented into vascepa, lovaza and others. The vascepa segment dominated the market in 2022. Vascepa (icosapent ethyl) was authorized by the FDA in 2012 to treat severe hypertriglyceridemia. Its approval was based on strong clinical evidence that it was beneficial in reducing excessive triglyceride levels, a significant risk factor for cardiovascular diseases.   

Based on application, the global omega 3 prescription drugs market has been segmented into hypertriglyceridemia and others. The hypertriglyceridemia segment dominated the market in 2022. The increased prevalence of hypertriglyceridemia is the primary driver of prescription Omega-3 medicines. Poor food, inactivity, and obesity are among the lifestyle variables that frequently contribute to high triglyceride levels.

Based on distribution channel, the global omega 3 prescription drugs market has been segmented into hospital pharmacy, retail pharmacy and online pharmacy. The retail pharmacy category generated the most income in 2022. They can address any concerns or questions, provide clarification on dosage recommendations, and educate patients on the benefits of taking Omega-3 prescription drugs, all of which enhance patient compliance and outcomes.

Regional Analysis

The global omega 3 prescription drugs market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe omega 3 prescription drugs market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The omega 3 prescription drugs market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World omega 3 prescription drugs market comprises of Middle East, Africa, and Latin America.

The North America Omega 3 prescription drugs Market dominated this market in 2022 (45.80%). North America is home to many of the leading pharmaceutical businesses that are developing Omega-3 medications. By investing in marketing, clinical trials, and research and development, these companies increase the accessibility and use of prescription Omega-3 drugs.

Moreover, the market share of omega 3 prescription medications in Europe is the second greatest. Much like many other developed regions, Europe is seeing an aging population. Prescription Omega-3 drugs are appropriate for treating age-related disorders like joint issues and cognitive decline, which are made necessary by the aforementioned demographic trend.

Additionally, the Asia-Pacific omega 3 prescription drugs market is expected to grow at the fastest CAGR from 2023 to 2032. The significant economic expansion taking place in the Asia Pacific region is contributing to the rise of the middle class. This group's increasing emphasis on health and wellness is driving the need for Omega-3 prescription drugs and supplements.

Furthermore, the rest of the world's omega 3 prescription drugs market is divided into the Middle East, Africa, and Latin America. The Latin America Omega-3 prescription drugs market is on the rise, driven by increasing health consciousness and awareness of the potential benefits of Omega-3 fatty acids. These drugs, known for their cardiovascular and anti-inflammatory properties, are gaining popularity as individuals seek preventive measures for various health conditions. Market growth is supported by collaborations between pharmaceutical companies and healthcare providers to offer effective Omega-3 treatments.

Key Findings of the Study

• The global Omega 3 prescription drugs market is expected to reach USD 2.8 Billion by 2032, at a CAGR of 9.20% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market the middle class is growing as a result of the substantial economic growth occurring in the Asia Pacific area.


• Based on distribution channel, the retail pharmacy segment was attributed to holding the largest market in 2022.


• Abbott; Amarin Pharmaceuticals Ireland Ltd.; GSK plc; Natrapharm, Inc. (Patriot Pharmaceutical Corp.); Viatris Inc.; Grupo Ferrer Internacional, S.A.; Camber Pharmaceuticals, Inc.; Dr. Reddy’s Laboratories Ltd.; Zydus Group; Hikma Pharmaceuticals PLC